An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 19 Sep 2022
At a glance
- Drugs Ofatumumab (Primary) ; Bendamustine
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals
- 01 Sep 2022 Results published in the Clinical Pharmacology in Drug Development
- 25 Jun 2017 Results (n=32) presented at the 22nd Congress of the European Haematology Association.
- 25 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.